AbbVie's approval delay raises further concerns about JAK drugs

AbbVie's approval delay raises further concerns about JAK drugs

Source: 
BioPharma Dive
snippet: 

The Food and Drug Administration may take up to three months longer to review an application from AbbVie to get Rinvoq, its marketed medicine for rheumatoid arthritis, also approved to treat active psoriatic arthritis. The company now expects a decision toward the end of the second quarter.